SynthesisPloS one2014
Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.Medicine · 2018Pooled it
- Article
- Zinc in Prostate Health and Disease: A Mini Review.Biomedicines · 2022Review
- Comparative cisplatin reactivity towards human Zn7-metallothionein-2 and MTF-1 zinc fingers: potential implications in anticancer drug resistance.Metallomics : integrated biometal science · 2022Article
- Metallothionein 2A with Antioxidant and Antitumor Activity Is Upregulated by Caffeic Acid Phenethyl Ester in Human Bladder Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2022Article
- The Critical Role of Ferroptosis in Hepatocellular Carcinoma.Frontiers in cell and developmental biology · 2022Review
- Expression profiles of metallothionein-I/II and megalin/LRP-2 in uterine cervical squamous lesions.Virchows Archiv : an international journal of pathology · 2021Article
- Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma.PloS one · 2020Article
- Microalgal Metallothioneins and Phytochelatins and Their Potential Use in Bioremediation.Frontiers in microbiology · 2020Review
- The Expression Profile and Prognostic Significance of Metallothionein Genes in Colorectal Cancer.International journal of molecular sciences · 2019Article
- A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.Scientific reports · 2019Article
- Metallothionein 3 Is a Hypoxia-Upregulated Oncogene Enhancing Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells.International journal of molecular sciences · 2019Article
- Expression of Metallothionein after Administration of Aspirin, Vitamin C or Zinc Supplement in the DMH Induced Colon Carcinoma in RatAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Differential metallothionein expression in oral lichen planus and amalgam-associated oral lichenoid lesions.Medicina oral, patologia oral y cirugia bucal · 2018Article
- Comparative gene expression profiling of human metallothionein-3 up-regulation in neuroblastoma cells and its impact on susceptibility to cisplatin.Oncotarget · 2018Article
- Metallothionein 1G promotes the differentiation of HT-29 human colorectal cancer cells.Oncology reports · 2017Article
- Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.Hepatology (Baltimore, Md.) · 2016Article
- Metallothionein regulates intracellular zinc signaling during CD4(+) T cell activation.BMC immunology · 2016Article
- Effect of HPV on tumor expression levels of the most commonly used markers in HNSCC.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- A Feedback Loop between Inflammation and Zn Uptake.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metallothionein (MT) has been extensively investigated as a molecular marker of various types of cancer. In spite of the fact that numerous reviews have been published in this field, no meta-analytical approach has been performed. Therefore, results of to-date immunohistochemistry-based studies were summarized using meta-analysis in this review. Web of science, PubMed, Embase and CENTRAL databases were searched (up to April 30, 2013) and the eligibility of individual studies and heterogeneity among the studies was assessed. Random and fixed effects model meta-analysis was employed depending on the heterogeneity, and publication bias was evaluated using funnel plots and Egger's tests. A total of 77 studies were included with 8,015 tissue samples (4,631 cases and 3,384 controls). A significantly positive association between MT staining and tumors (vs. healthy tissues) was observed in head and neck (odds ratio, OR 9.95; 95% CI 5.82-17.03) and ovarian tumors (OR 7.83; 1.09-56.29), and a negative association was ascertained in liver tumors (OR 0.10; 0.03-0.30). No significant associations were identified in breast, colorectal, prostate, thyroid, stomach, bladder, kidney, gallbladder, and uterine cancers and in melanoma. While no associations were identified between MT and tumor staging, a positive association was identified with the tumor grade (OR 1.58; 1.08-2.30). In particular, strong associations were observed in breast, ovarian, uterine and prostate cancers. Borderline significant association of metastatic status and MT staining were determined (OR 1.59; 1.03-2.46), particularly in esophageal cancer. Additionally, a significant association between the patient prognosis and MT staining was also demonstrated (hazard ratio 2.04; 1.47-2.81). However, a high degree of inconsistence was observed in several tumor types, including colorectal, kidney and prostate cancer. Despite the ambiguity in some tumor types, conclusive results are provided in the tumors of head and neck, ovary and liver and in relation to the tumor grade and patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.